Zenas BioPharma Announces $225 Million IPO

New York – September 16, 2024 – Cooley advised Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities as the underwriters of Zenas BioPharma’s $225 million initial public offering. Zenas is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Zenas issued and sold 13,235,294 shares of its common stock priced at $17 per share, with a 30-day option for the underwriters to purchase up to 1,985,294 additional shares. Zenas began trading on the Nasdaq Global Select Market on September 13, 2024, under the ticker symbol ZBIO.

Lawyers Richard Segal, Denny Won, Div Gupta and Evan Leitner led the Cooley team advising the underwriters.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.